Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an extension study study to investigate long term safety of SyB L-1101 when administered intravenously every 4 weeks to the patients who have completed 8 cycles in the study 2011005 whose purpose is to investigate tolerability of SyB L-1101 when administered intravenously in patients with recurrent/relapsed or refractory myelodysplastic syndrome. Antitumor effects will also be investigated in this study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SyB L-1101 | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SyB L-1101 | Drug | SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle. |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events | Total number affected by any adverse events (details are presented in adverse event section) | Up to 20 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Disease Response Assessment | Disease progression According to the International Working Group 2006 response criteria for Myelodysplastic Syndrome, "disease progression" is defined as no evidence of complete remission (CR), partial remission, marrow CR, stable disease, or failure, and as meeting one of the following conditions.
|
Not provided
Inclusion Criteria:
Patients must satisfy the following conditions listed below.
Patients enrolled in the study 2011005 of SyB L-1101 in Patients With Myelodysplastic Syndrome.
Patients who was not judged as disease progression* nor progressive disease/relapsed** at the end of the cycle 8 in the study 2011005. * hematologic remission according to IWG 2006 criteria ** hematologic improvement according to IWG 2006 criteria
Patients who met the continuation criteria*** after Cycle 8 week 2 (Day 15±3) in the study 2011005.***defined in the study 2011005 protocol
Patients who can be expected to survive at least three months or longer.
Patients who have score of 0 to 2 in Eastern Cooperative Oncology Grou (ECOG) Performance Status (P.S.).
Patients with adequate function in major organs (heart, lungs, liver, kidneys, etc.).
Patients who personally signed an informed consent document for participation in this study.
Exclusion Criteria:
Patients who satisfy any of the following conditions will not be enrolled in the study.
Patients with anemia (haemolytic anaemia, gastrointestinal haemorrhage, etc.) caused by factors other than MDS.
Patients with obvious infectious diseases (including viral infections).
Patients with serious complications (liver failure, renal failure, etc.).
Patients with a complication of serious heart disease (myocardial infarction, ischemic heart disease, etc.)
Patients with a serious gastrointestinal condition (severe or significant nausea/vomiting, diarrhea, etc.)
Patients with serious bleeding tendencies (disseminated intravascular coagulation (DIC), internal hemorrhage, etc.).
Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of <130 milliequivalent/L).
Patients with an addiction to a legal or illegal drug, or with alcohol dependency.
Patients who are nursing, pregnant or may become pregnant.
Patients who have not consented to the following contraceptive measures. Patients will avoid sexual intercourse with sexual partners or should use the following contraceptive methods in these time periods: for male patients during the administration period of the trial and for six months after the end of administration; female patients during the administration period of the trial, and until a second menstrual period is confirmed after the end of administration (or in the case of female patients with no menstrual period, for two months after the end of administration). (1) Male patients:The patient will always use a condom. For effective contraception, it is recommended that the female partner also use the contraceptive methods for female patients. (2) Female patients: Female patients who may become pregnant should use one or more types of the following contraceptive methods. In addition, the male partner will always use a condom.
Other patients judged to be unsuitable by an investigator or sub-investigator.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Katsuhisa Goto | SymBio Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Nagoya | Aichi-ken | Japan | |||
| Research Site |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | SyB L-1101 | SyB L-1101 （rigosertib sodium for intravenous formulation）: A 72-hour continuous intravenous dosing of SyB L-1101 4 weeks apart were administered to patients who had no disease progression of the primary disease at the end of the eighth cycle of Study 2011005, as well as those who gave consent to the continuous administration. The dose of SyB L-1101 in the ninth cycle was to be the same as that of the eighth cycle of Study 2011005 (if a dose reduction in the next cycle applied to a patient, SyB L-1101 was administered to the patient at the reduced dose). |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Up to 20 weeks |
| Serious Adverse Events | Total number affected any serious adverse events | Up to 20 weeks |
| Hematologic Improvement | NCA (not considered assessable) no evidence of hematologic improvement -erythroid, -platelet, -neutrophil, progressive disease, or relapse, defined in the International Working Group 2006 response criteria for myelodysplastic syndrome. | Up to 20 weeks |
| Cytogenetic Response | NCA (not considered assessable) no evidence of cytogenetic response, defined in the International Working Group 2006 response criteria for myelodysplastic syndrome. | Up to 20 weeks |
| Fukuoka |
| Fukuoka |
| Japan |
| Research Site | Kagoshima | Kagoshima-ken | Japan |
| Research site | Isesaki | Kanagawa | Japan |
| Research Site | Kumamoto | Kumamoto | Japan |
| Research Site | Sendai | Miyagi | Japan |
| Research Site | Kurashiki | Okayama-ken | Japan |
| Research Site | Kawagoe | Saitama | Japan |
| Research Site | Tokyo | Tokyo | Japan |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SyB L-1101 | SyB L-1101 （rigosertib sodium for intravenous formulation）: A 72-hour continuous intravenous dosing of SyB L-1101 4 weeks apart were administered to patients who had no disease progression of the primary disease at the end of the eighth cycle of Study 2011005, as well as those who gave consent to the continuous administration. The dose of SyB L-1101 in the ninth cycle was to be the same as that of the eighth cycle of Study 2011005 (if a dose reduction in the next cycle applied to a patient, SyB L-1101 was administered to the patient at the reduced dose). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | participants |
| ||||||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Adverse Events | Total number affected by any adverse events (details are presented in adverse event section) | Posted | Number | participants | Up to 20 weeks |
|
|
| |||||||||||||||||||||||||||
| Secondary | Disease Response Assessment | Disease progression According to the International Working Group 2006 response criteria for Myelodysplastic Syndrome, "disease progression" is defined as no evidence of complete remission (CR), partial remission, marrow CR, stable disease, or failure, and as meeting one of the following conditions.
| Posted | Number | participants | Up to 20 weeks |
| |||||||||||||||||||||||||||||
| Secondary | Serious Adverse Events | Total number affected any serious adverse events | Posted | Number | participants | Up to 20 weeks |
|
| ||||||||||||||||||||||||||||
| Secondary | Hematologic Improvement | NCA (not considered assessable) no evidence of hematologic improvement -erythroid, -platelet, -neutrophil, progressive disease, or relapse, defined in the International Working Group 2006 response criteria for myelodysplastic syndrome. | Posted | Number | participants | Up to 20 weeks |
|
| ||||||||||||||||||||||||||||
| Secondary | Cytogenetic Response | NCA (not considered assessable) no evidence of cytogenetic response, defined in the International Working Group 2006 response criteria for myelodysplastic syndrome. | Posted | Number | participants | Up to 20 weeks |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SyB L-1101 | SyB L-1101 （rigosertib sodium for intravenous formulation）: A 72-hour continuous intravenous dosing of SyB L-1101 4 weeks apart were administered to patients who had no disease progression of the primary disease at the end of the eighth cycle of Study 2011005, as well as those who gave consent to the continuous administration. The dose of SyB L-1101 in the ninth cycle was to be the same as that of the eighth cycle of Study 2011005 (if a dose reduction in the next cycle applied to a patient, SyB L-1101 was administered to the patient at the reduced dose). | 0 | 1 | 1 | 1 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pruritus | Skin and subcutaneous tissue disorders |
| |||
| Rash | Skin and subcutaneous tissue disorders |
| |||
| Splenomegaly | Blood and lymphatic system disorders |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Katsuhisa Goto | SymBio Pharmaceuticals | +81-3-5472-1127 |
| ID | Term |
|---|---|
| D009190 | Myelodysplastic Syndromes |
| ID | Term |
|---|---|
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|